Teachers Advisors LLC raised its holdings in Eli Lilly and Co (NYSE:LLY) by 1.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,962,939 shares of the company’s stock after buying an additional 33,724 shares during the quarter. Teachers Advisors LLC owned 0.18% of Eli Lilly and worth $165,790,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Avestar Capital LLC acquired a new position in Eli Lilly and in the fourth quarter valued at approximately $100,000. Gradient Investments LLC acquired a new position in Eli Lilly and in the fourth quarter valued at approximately $103,000. MPS Loria Financial Planners LLC acquired a new position in Eli Lilly and in the second quarter valued at approximately $128,000. San Francisco Sentry Investment Group CA acquired a new position in Eli Lilly and in the second quarter valued at approximately $129,000. Finally, Front Row Advisors LLC acquired a new position in shares of Eli Lilly and during the fourth quarter worth approximately $137,000. 77.58% of the stock is currently owned by hedge funds and other institutional investors.
A number of brokerages have recently weighed in on LLY. Goldman Sachs Group lowered Eli Lilly and from a “buy” rating to a “neutral” rating and upped their target price for the stock from $86.98 to $95.00 in a research report on Tuesday, January 16th. Jefferies Group set a $100.00 target price on Eli Lilly and and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Credit Suisse Group reaffirmed a “hold” rating on shares of Eli Lilly and in a research report on Wednesday, December 13th. BMO Capital Markets set a $73.00 target price on Eli Lilly and and gave the stock a “sell” rating in a research report on Tuesday, December 12th. Finally, Argus raised Eli Lilly and from a “hold” rating to a “buy” rating and upped their target price for the stock from $85.52 to $115.00 in a research report on Friday, January 5th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company’s stock. Eli Lilly and has an average rating of “Hold” and a consensus price target of $93.47.
Shares of Eli Lilly and Co (NYSE:LLY) opened at $79.61 on Monday. The company has a market capitalization of $87,220.55, a price-to-earnings ratio of 18.60, a P/E/G ratio of 1.48 and a beta of 0.28. Eli Lilly and Co has a 12-month low of $73.69 and a 12-month high of $89.09. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.32 and a quick ratio of 1.01.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. The business had revenue of $6.16 billion during the quarter, compared to analyst estimates of $5.93 billion. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. Eli Lilly and’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.95 EPS. equities analysts anticipate that Eli Lilly and Co will post 4.87 earnings per share for the current fiscal year.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.